BACKGROUND: The induction of apoptosis might be a promising treatment for cancers refractory to conventional therapies, such as esophageal cancer. In this study, we examined whether epidermal growth factor-induced growth inhibition results from apoptosis of esophageal squamous cell carcinoma (SCC) cells as a result of STAT1 activation and evaluated whether interferon gamma (IFN-gamma) can induce apoptosis of cancer cells in vivo. METHODS: To assess the function of STAT1, we established stable transfectants expressing dominant-negative STAT1. Apoptosis was assessed by several experimental techniques, including flow cytometry. Differentiation was evaluated by Western blot test with involucrin used as a marker. In vivo, cancer cells were injected into male BALB/c nu/nu mice. Two weeks later, the mice started to receive injections of IFN-gamma or saline into a tail vein four times per week. Concentrations of IFN-gamma in the tumors were analyzed by enzyme-linked immunosorbent assay. Apoptosis was evaluated by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining. RESULTS: Epidermal growth factor inhibited the growth of esophageal SCC cells by causing apoptosis through several pathways involving STAT1 activation. IFN-gamma induced the apoptosis of cancer cells, but it also promoted the differentiation (not apoptosis) of primary cultured cells derived from normal esophageal epithelium. IFN-gamma also inhibited the growth of xenograft tumors of esophageal SCC cells in vivo. CONCLUSIONS: Our results suggest that IFN-gamma is one candidate for cytokine-based therapy of cancer. IFN-gamma-induced STAT1 activation might be involved in the apoptosis of esophageal SCC cells and in the terminal differentiation of normal squamous cells. Further studies of STAT1 signaling pathways may provide the basis for new targeted therapeutic strategies for esophageal SCC.
BACKGROUND: The induction of apoptosis might be a promising treatment for cancers refractory to conventional therapies, such as esophageal cancer. In this study, we examined whether epidermal growth factor-induced growth inhibition results from apoptosis of esophageal squamous cell carcinoma (SCC) cells as a result of STAT1 activation and evaluated whether interferon gamma (IFN-gamma) can induce apoptosis of cancer cells in vivo. METHODS: To assess the function of STAT1, we established stable transfectants expressing dominant-negative STAT1. Apoptosis was assessed by several experimental techniques, including flow cytometry. Differentiation was evaluated by Western blot test with involucrin used as a marker. In vivo, cancer cells were injected into male BALB/c nu/nu mice. Two weeks later, the mice started to receive injections of IFN-gamma or saline into a tail vein four times per week. Concentrations of IFN-gamma in the tumors were analyzed by enzyme-linked immunosorbent assay. Apoptosis was evaluated by TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining. RESULTS: Epidermal growth factor inhibited the growth of esophageal SCC cells by causing apoptosis through several pathways involving STAT1 activation. IFN-gamma induced the apoptosis of cancer cells, but it also promoted the differentiation (not apoptosis) of primary cultured cells derived from normal esophageal epithelium. IFN-gamma also inhibited the growth of xenograft tumors of esophageal SCC cells in vivo. CONCLUSIONS: Our results suggest that IFN-gamma is one candidate for cytokine-based therapy of cancer. IFN-gamma-induced STAT1 activation might be involved in the apoptosis of esophageal SCC cells and in the terminal differentiation of normal squamous cells. Further studies of STAT1 signaling pathways may provide the basis for new targeted therapeutic strategies for esophageal SCC.
Authors: Trisha R Stankiewicz; F Alexandra Loucks; Emily K Schroeder; Marja T Nevalainen; Kenneth L Tyler; Klaus Aktories; Ron J Bouchard; Daniel A Linseman Journal: J Biol Chem Date: 2012-02-29 Impact factor: 5.157
Authors: C E Delsing; C P Bleeker-Rovers; F L van de Veerdonk; J Tol; J W M van der Meer; B J Kullberg; M G Netea Journal: Med Mycol Case Rep Date: 2012-03-01
Authors: Loren J Martin; Shad B Smith; Arkady Khoutorsky; Claire A Magnussen; Alexander Samoshkin; Robert E Sorge; Chulmin Cho; Noosha Yosefpour; Sivaani Sivaselvachandran; Sarasa Tohyama; Tiffany Cole; Thang M Khuong; Ellen Mir; Dustin G Gibson; Jeffrey S Wieskopf; Susana G Sotocinal; Jean Sebastien Austin; Carolina B Meloto; Joseph H Gitt; Christos Gkogkas; Nahum Sonenberg; Joel D Greenspan; Roger B Fillingim; Richard Ohrbach; Gary D Slade; Charles Knott; Ronald Dubner; Andrea G Nackley; Alfredo Ribeiro-da-Silva; G Gregory Neely; William Maixner; Dmitri V Zaykin; Jeffrey S Mogil; Luda Diatchenko Journal: J Clin Invest Date: 2017-08-07 Impact factor: 14.808
Authors: Nicole N Scheff; Yi Ye; Zachary R Conley; Jen Wui Quan; Yat Vong Ronald Lam; Richard Klares; Kamalpreet Singh; Brian L Schmidt; Bradley E Aouizerat Journal: Pain Date: 2020-10 Impact factor: 7.926